Monthly Archives: September 2011
Nycomed and Almirall announce licensing agreement for ebastine in Asia
Nycomed and Almirall have announced that they have signed a licensing and supply agreement for Almirall’s antihistamine ebastina, under the trademark Kestine, indicated for allergic rhinitis and chronic idiopathic urticaria, in China and other key emerging markets. Under the terms … Continue reading
Filed under alliances
Graceway Pharmaceuticals files for bankruptcy protection
Graceway Pharmaceuticals, a maker of skin treatments and asthma medication, has sought bankruptcy protection with a plan to sell its assets to Galderma for $275 million. Graceway cited the loss of patent protection on Aldara, a cream used to treat … Continue reading
Filed under bankruptcy
Santen Pharmaceutical acquires Novagali Pharma
Santen Pharmaceutical, a Japanese pharmaceutical company, and Novagali Pharma, a French biopharmaceutical company specializing in ophthalmology and ocular therapeutics, have announced that Santen will acquire a controlling interest in Novagali. Santen develops ophthalmic products. Among prescription ophthalmic pharmaceuticals, Santen has … Continue reading
Filed under acquisitions
Neurosearch to cut workforce by 82.5% over the next two years in effort to conserve cash
Neurosearch has announced a restructuring and discontinuation of its other activities designed to conserve financial and management resources to complete the development of Huntexil its treatment for motor symptoms in Huntington’s disease. The company has adjusted its financial guidance from … Continue reading
Filed under funding
H. Lundbeck and Proximagen sign CNS collaboration
H. Lundbeck and Proximagen have announced that they have entered into a partnershipagreement designed to formalise a CNS-focused partnership between the two companies. As part of the Agreement, a steering committee involving representatives from both companies will focus on developing … Continue reading
Filed under alliances
Merck ends Johnson & Johnson joint venture
Merck has announced that it is selling its 50% interest in a joint venture with Johnson & Johnson over a collection of over-the-counter products, including the heartburn remedies Mylanta and Pepcid. Under the agreement, Merck will receive a one-time payment … Continue reading
Filed under joint ventures
Biotie Therapies merges with Newron in $63 million deal
Biotie Therapies has signed a deal to acquire Newron Pharmaceuticals for up to $63 million worth of shares. Newron has reported losses totaling about $60 million over the past two years. Newron ran into trouble in the spring of 2010 … Continue reading
Filed under acquisitions
Mesoblast and Lonza sign stem cell alliance
Mesoblast and Lonza have announced that they have entered into a strategic alliance for clinical and long-term commercial production of Mesoblast’s off-the-shelf adult stem cell products. Under the agreement Lonza will supply Mesoblast’s clinical and long-term commercial Mesenchymal Precursor Cell … Continue reading
Filed under alliances
Vectura earns $5 million milestone payment from Novartis
Vectura has announced that NVA237 (glycopyrronium bromide), a long-acting muscarinic antagonist (LAMA) being investigated as a once-daily treatment for chronic obstructive pulmonary disease, has been filed by Novartis for marketing authorisation with the European Medicines Agency under the brand-name Seebri … Continue reading
Filed under alliances
Si-Bone closes $16 million Series C funding round
Si-Bone a medical device company focused on minimally-invasive approaches to sacroiliac joint disruptions and degenerative sacroiliitis, has announced that it has closed a $16 million Series C funding round. Participants include Montreux Equity Partners and Skyline Ventures.
Filed under funding
